Podcasts about Boehringer

Esto es un extracto de la Tertulia de AutoFM que se emite cada jueves en Onda Cero Comentamos cómo ha afectado el apagón a la industria española, especialmente a la de la automoción y detalles sobre el rearranque de las fábricas de coches en España. • Parón industrial masivo tras el gran apagón en la Península • El corte eléctrico del 29 de abril dejó sin suministro a España y Portugal, forzando paradas de emergencia en refinerías (Petronor Muskiz, Repsol Tarragona, Cepsa/Moeve) y activando antorchas de seguridad con visibles columnas de humo. • Las plantas siguen detenidas y no hay fecha de reactivación; el impacto económico aún no se ha podido cuantificar. • Automoción: más de 4 000 vehículos sin producir y líneas paralizadas • Ford Almussafes, VW Landaben, Seat Martorell, Ebro Factory y otros centros detuvieron todas las cadenas a las 12:30 h; generadores propios no cubren la demanda total. • Fabricantes evalúan añadir turnos de fin de semana en mayo para recuperar atrasos; de momento se descartan ERTE y se aplicará bolsa de horas. • Efectos en siderurgia, química y proveedores • La siderúrgica Celsa y firmas petroquímicas de Tarragona interrumpieron operaciones de alto consumo energético. • Proveedores de componentes de automoción y otras grandes industrias también frenaron producción a la espera de restablecer el sistema eléctrico. • Sector farmacéutico y pymes: resiliencia parcial • Multinacionales como Grifols y Boehringer mantuvieron actividad gracias a grupos electrógenos; patronales aconsejan priorizar comunicaciones y seguridad con generadores propios. • El incidente revela la vulnerabilidad del tejido productivo ante interrupciones súbitas y la dificultad de reiniciar plantas complejas. • Riesgos sistémicos y contexto • Red Eléctrica investiga la causa del colapso; la dependencia de renovables y el papel crítico de la nuclear vuelven al debate. • El apagón llegó días después de que Repsol alertara de un gran fallo de suministro en Cartagena, subrayando la necesidad de planes de contingencia energética. 1. Activación del Plan de Contingencia y Comité de Crisis 1.1 Inmediatamente después del blackout, convoque al Comité de Crisis (Dirección de Planta, Mantenimiento, EHS, Calidad, IT/OT, Producción, Utilities). 1.2 Compruebe que el Manual de Plan de Contingencia Eléctrica (versión vigente) esté a mano en sala de Control. 1.3 Designe a un Coordinador de Re-arranque que centralice la comunicación con el Centro de Control Eléctrico (REE o distribuidora local) y con los responsables de área. 2. Aseguramiento inmediato de la seguridad operacional 2.1 Verifique que todas las líneas se encuentran mecanicamente bloqueadas (paros de emergencia, enclavamientos de prensas, robots en posición segura, válvulas neumáticas cerradas). 2.2 Confirme la activación de UPS y grupos electrógenos críticos (servicios contra-incendios, servidores MES/ERP, iluminación de evacuación). 2.3 Realice un pase de seguridad por todas las áreas de alto riesgo: soldadura robotizada, cabinas de pintura con compuestos volátiles, pits de prensas y fosos de catforesis. 3. Evaluación del estado de suministro y calidad eléctrica 3.1 Reciba confirmación oficial de la energía de retorno (grid OK). 3.2 Revise parámetros de calidad: tensión (±5 %), frecuencia (49,8-50,2 Hz), THD (0,95). 3.3 Realice pruebas de carga gradual en CCMs secundarios antes de energizar MCCs de proceso. 4. Inspección eléctrica y de utilidades internas 4.1 Compruebe interruptores de potencia, fusibles, barras y tierras en subestación 30/6 kV y celdas de media tensión. 4.2 Inspeccione transformadores de distribución: nivel de aceite, temperatura y ΔP en bombas ONAN/ONAF. 4.3 Verifique arranque secuencial de compresores de aire, grupos de refrigeración, calderas y HVAC de cabinas. 5. Revisión de equipos de proceso y sistemas de control 5.1 Realice checklist mecánico-eléctrico en:  • Prensas Transfer & Tandem: nivel hidráulico, enclavamientos, finales de carrera.  • Robots soldadura: home position, circuitos de agua/glycol, pinzas.  • Catenarias de pintura: tensiones de cadena, sensórica de posición.  • AGVs y EMS: estado de baterías, comunicaciones Wi-Fi/5G. 5.2 Reinicie secuencialmente PLCs y Safety-PLC; valide checksum de programas y tiempos de ciclo. 5.3 Arranque servidores MES, SCADA y dispositivos IoT; compruebe sincronismo con ERP; habilite interconexión EDI con proveedores Just-in-Time. 6. Pruebas en vacío y con “racks testigo” 6.1 Ejecute “dry-run” de cada línea (sin piezas) para observar vibraciones, paradas inesperadas o alarms críticas. 6.2 Introduzca racks testigo (carrocerías dummy, bastidores de tren motriz) y realice el primer First-Off controlado por Calidad. 6.3 Liberación gradual: Soldadura > Pintura > Montaje final > Pruebas de pista interna. 7. Validación de Calidad y recalibración de procesos 7.1 Dimensional: pase de carrocería por CMM y láser gap-flush; tolerancias ISO 8062/8015. 7.2 Pintura: ensayo de espesor (μm), adhesión (cross-cut), brillos (GU) y cabina clase A. 7.3 Powertrain: correas de rodaje y dinamómetro en banco EoL; correlación con SPC histórico. 7.4 Ajuste fino de parámetros si se detectan derivas >1 σ respecto al CP/CPK nominal. 8. Reactivación de logística interna y externa 8.1 Reinicie kanban y milk-run; notifique a proveedores Tier 1/Tier 2 el ETR (Estimated Time to Resume). 8.2 Verifique que almacenes automatizados (AS/RS) y shuttle conveyors funcionan con inventario correcto. 8.3 Establezca plan de recuperación de volumen: horas extras, turnos de fin de semana, line-balancing temporal. 9. Comunicación y reporting 9.1 Informe interno a Dirección y casa matriz: duración de parada, líneas afectadas, producción perdida, OEE estimado, coste preliminar. 9.2 Parte a autoridades laborales/regionales si procede (>4 h de parada o activación de plan de emergencia). 9.3 Comunicación transparente a clientela OEM (si planta de componentes) o red comercial (si planta vehículo completo) con nuevo week-plan de envíos. 10. Revisión post-evento y acciones de robustez 10.1 Reunión “hot-wash” 24 h después: listado de incidencias, MTTR, piezas dañadas, mejoras de mantenimiento predictivo. 10.2 Actualizar Plan de Continuidad de Negocio:  • Capacidad mínima de back-up (generadores diésel >20 % demanda pico).  • Protecciones de sobretensión y almacenamiento energético (BESS).  • Prácticas ciberseguras OT-IT (segmented VLAN, firewalls, backups off-line). 10.3 Programar simulacro anual de pérdida total de red para verificar tiempos de respuesta y ajuste de roles. Todos los podcast: https://www.podcastmotor.es Twitter: @AutoFmRadio Instagram: https://www.instagram.com/autofmradio/ YouTube: https://www.youtube.com/@AutoFM Contacto: info@autofm.es

Noch wollen sich Boehringer, Schott, Juwi, u.a. nicht einschüchtern lassen. Wird das so bleiben? ++ Warum Diversität auch ökonomisch wichtig ist – Interview mit einer Professorin für Personalmanagement ++ Wie GEFI-Matratzen aus Bammental als Kleinbetrieb große Kunden halten kann

An NFL Superstar on being Better Than Before - Jane's special guest today is Brian Dawkins, a football legend as one of the greatest NFL Safeties of all time. Brian, viewed as the leader of the Philadelphia Eagles' defense, was named to an astonishing nine Pro Bowls and five All-Pro teams during his career, including thirteen 13 seasons with the now World Champs. It is therefore not surprising that in 2018 Brian was also inducted into the Pro Football Hall of Fame. In a nutshell, his impact on the Eagles and the NFL as a whole will never be forgotten. Currently, he's also bringing his knowledge and wherewithal to the health arena, by using his platform to help spread awareness and education about chronic kidney disease. To that end, he is representing Boehringer & Lilly's It Takes 2 health initiative. On this segment, Jane and Brian discuss this campaign, as well as who inspired him to have a career in sports, the importance of sports, including having an outlet for getting rid of negative energy, and how his love of the game created a drive for mental toughness. Brian also talks about how  the concept of wellness has changed over the years, and his personal health and nutrition program. Finally, he shares the life lessons he learned throughout his career that will help all our listeners become Better Than Before. 

How can pharmaceutical companies best navigate setbacks in drug development to deliver breakthroughs in R&D? Find out in this week's episode, where Isabel and Jade share an interview with Christoph von der Goltz, Global Head of Medicine Central Nervous System and Emerging Areas, Boehringer Ingelheim.  Together, he and Jade explore the ins and outs of drug failure, whether to pivot or persevere after an R&D setback, how to better break the stigma of mental illness and much more.  A little more on EMJ GOLD's guest…  Christoph von der Goltz is Global Head of Medicine Central Nervous System and Emerging Areas at Boehringer Ingelheim. He has more than 15 years of experience in a variety of roles in pharmaceutical R&D. He is also a board-certified psychiatrist with more than 10 years of clinical experience in neurology and psychiatry and academic research in preclinical, clinical and public health projects in Germany and Sweden. 

Küpper, Moritz www.deutschlandfunk.de, Informationen am Mittag

Peter Boehringer, Chairman of the Budgetary Committee of the German Bundestag (AfD), and Schiller Institute's Harley Schlanger, join the program to discuss the devolution towards tyranny in Germany and elsewhere in Europe. We discuss the latest JD Vance speech in Munich Germany and the reactions of the establishment. We then discuss the changing worldwide monetary policies and the instability power shifts in global currencies and systems have caused throughout history. This is a stimulating conversation that will get even the most savvy listener thinking hard about current events.Harley Schlanger: https://laroucheorganization.com/HarleySchlangerReportPeter Boehringer: https://pboehringer.de

Tyranny in Europe: Germany's AfD Scares Establishment, Peter Boehringer(AfD) & Harley Schlanger - SarahWestall.com

Welcome to episode 131. If you are a healthcare communications agency owner, or an account manager working in healthcare communications, and you're looking to stay ahead in the ever-evolving world of pharmaceutical marketing, then this episode is for you. I'm joined in the studio by Jonathan Gwillim and Kate Eversole from PharmaBrands. They are the organisers of the upcoming Age of AI Europe event, which, if you're listening or watching this at the beginning of 2025, is happening on March 4th in London. This is Europe's leading conference in GenAI in healthcare marketing and it features expert speakers from companies like Google, AstraZeneca, Novartis, ITV, Novo, Nordisk, Boehringer, Ingelheim and many more. In this episode, Jonathan and Kate share of insights about how healthcare agencies and their clients are using GenAI right now. They also share how creative directors feel about Gen AI's impact on the industry, and Kate also shares practical steps you can take as an account manager to confidently embrace AI in your role and some tips for having conversations with your clients. You can connect with Kate and Jonathan via LinkedIn: https://www.linkedin.com/in/kateeversole/ https://www.linkedin.com/in/jongwillim/ There were several resources and links mentioned in our recording: The Age of AI event, March 4, London: https://www.pharmabrands.ca/age-of-ai-europe PharmaBrands report on AI literacy: https://cdn.prod.website-files.com/65b7dd23f5d4facb3c95fdf7/678e3106eb089ba6a175a282_AI%20Literacy%20Report_2025%20(3).pdf Free webinar on Gen AI 101 : https://www.pharmabrands.ca/webinar Klick and Guardrail reference: https://www.klick.com/news/ai-compliance-breakthrough-wins-klick-prize-results-signal-industry-trends Recommended newsletter from Klick on all things health marketing: https://www.klick.com/klickwire Syneos Health reference: https://pmsociety.org.uk/results/pm-society-digital-awards-2024-results/pm-society-digital-awards-2024-digital-agency-of-the-year/ & their trends report: https://www.syneoshealth.com/insights-hub/2025-health-trends Pfizer and Publicis reference: https://digiday.com/marketing/with-charlie-pfizer-is-building-a-new-generative-ai-platform-for-pharma-marketing/ Sanofi reference: https://www.forbes.com/sites/alexzhavoronkov/2023/06/21/sanofi-goes-all-in-on-ai/ Novo Nordisk reference: https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/cmd/2024/P10-Data-Science-and-AI.pdf AI driven Video - Cires 21: https://www.cires21.com/ Text to speech leader - Eleven labs: https://elevenlabs.io/ Great content on marketing AI - Marketing AI institute: https://www.marketingaiinstitute.com/ Tool to reduce meetings - Loom: https://www.loom.com/

Lesbians and the Law The Lesbian Historic Motif Podcast - Episode 305 with Heather Rose Jones In this episode we talk about: Evidence for how romantic and sexual relations between women were treated in legal systems in western culture References Benbow, R. Mark and Alasdair D. K. Hawkyard. 1994. “Legal Records of Cross-dressing” in Gender in Play on the Shakespearean Stage: Boy Heroines and Female Pages, ed. Michael Shapiro, Ann Arbor. pp.225-34. Benkov, Edith. “The Erased Lesbian: Sodomy and the Legal Tradition in Medieval Europe” in Same Sex Love and Desire Among Women in the Middle Ages. ed. by Francesca Canadé Sautman & Pamela Sheingorn. Palgrave, New York, 2001. Boehringer, Sandra (trans. Anna Preger). 2021. Female Homosexuality in Ancient Greece and Rome. Routledge, New York. ISBN 978-0-367-74476-2 Borris, Kenneth (ed). 2004. Same-Sex Desire in the English Renaissance: A Sourcebook of Texts, 1470-1650. Routledge, New York. ISBN 978-1-138-87953-9 Brown, Kathleen. 1995. “'Changed...into the Fashion of a Man': The Politics of Sexual Difference in a Seventeenth-Century Anglo-American Settlement” in Journal of the History of Sexuality 6:2 pp.171-193. Burshatin, Israel. “Elena Alias Eleno: Genders, Sexualities, and ‘Race' in the Mirror of Natural History in Sixteenth-Century Spain” in Ramet, Sabrina Petra (ed). 1996. Gender Reversals and Gender Cultures: Anthropological and Historical Perspectives. Routledge, London. ISBN 0-415-11483-7 Crane, Susan. 1996. “Clothing and Gender Definition: Joan of Arc,” in Journal of Medieval and Early Modern Studies 26:2 : 297-320. Crawford, Patricia & Sara Mendelson. 1995. "Sexual Identities in Early Modern England: The Marriage of Two Women in 1680" in Gender and History vol 7, no 3: 362-377. Cressy, David. 1996. “Gender Trouble and Cross-Dressing in Early Modern England” in Journal of British Studies 35/4: 438-465. Crompton, Louis. 1985. “The Myth of Lesbian Impunity: Capital Laws from 1270 to 1791” in Licata, Salvatore J. & Robert P. Petersen (eds). The Gay Past: A Collection of Historical Essays. Harrington Park Press, New York. ISBN 0-918393-11-6 (Also published as Journal of Homosexuality, Vol. 6, numbers 1/2, Fall/Winter 1980.) Dekker, Rudolf M. and van de Pol, Lotte C. 1989. The Tradition of Female Transvestism in Early Modern Europe. Macmillan, London. ISBN 0-333-41253-2 Derry, Caroline. 2020. Lesbianism and the Criminal Law: Three Centuries of Legal Regulation in England and Wales. Palgrave Macmillan. ISBN 978-3-030-35299-8 Duggan, Lisa. 1993. “The Trials of Alice Mitchell: Sensationalism, Sexology and the Lesbian Subject in Turn-of-the-Century America” in Queer Studies: An Interdisciplinary Reader, ed. Robert J. Corber and Stephen Valocchi. Oxford: Blackwell. pp.73-87 Eriksson, Brigitte. 1985. “A Lesbian Execution in Germany, 1721: The Trial Records” in Licata, Salvatore J. & Robert P. Petersen (eds). The Gay Past: A Collection of Historical Essays. Harrington Park Press, New York. ISBN 0-918393-11-6 (Also published as Journal of Homosexuality, Vol. 6, numbers 1/2, Fall/Winter 1980.) Fernandez, André. 1997. “The Repression of Sexual Behavior by the Aragonese Inquisition between 1560 and 1700” in Journal of the History of Sexuality 7:4 pp.469-501 Friedli, Lynne. 1987. “Passing Women: A Study of Gender Boundaries in the Eighteenth Century” in Rousseau, G. S. and Roy Porter (eds). Sexual Underworlds of the Enlightenment. Manchester University Press, Manchester. ISBN 0-8078-1782-1 Hindmarch-Watson, Katie. 2008. "Lois Schwich, the Female Errand Boy: Narratives of Female Cross-Dressing in Late-Victorian London" in GLQ 14:1, 69-98. History Project, The. 1998. Improper Bostonians. Beacon Press, Boston. ISBN 0-8070-7948-0 Holler, Jacqueline. 1999. “'More Sins than the Queen of England': Marina de San Miguel before the Mexican Inquisition” in Women in the Inquisition: Spain and the New World, ed. Mary E. Giles. Johns Hopkins University Press, Baltimore. ISBN 0-8018-5931-X pp.209-28 Hubbard, Thomas K. 2003. Homosexuality in Greece and Rome: A Sourcebook of Basic Documents. University of California Press, Berkeley. ISBN 978-0-520-23430-7 Hutchison, Emily & Sara McDougall. 2022. “Pardonable Sodomy: Uncovering Laurence's Sin and Recovering the Range of the Possible” in Medieval People, vol. 37, pp. 115-146. Karras, Ruth Mazo. 2005. Sexuality in Medieval Europe: Doing Unto Others. Routledge, New York. ISBN 978-0-415-28963-4 Lansing, Carol. 2005. “Donna con Donna? A 1295 Inquest into Female Sodomy” in Studies in Medieval and Renaissance History: Sexuality and Culture in Medieval and Renaissance Europe, Third Series vol. II: 109-122. Lucas, R. Valerie. 1988. “'Hic Mulier': The Female Transvestite in Early Modern England” in Renaissance and Reformation 12:1 pp.65-84 Merrick, Jeffrey & Bryant T. Ragan, Jr. 2001. Homosexuality in Early Modern France: A Documentary Collection. Oxford University Press, New York. ISBN 0-19-510257-6 Michelsen, Jakob. 1996. “Von Kaufleuten, Waisenknaben und Frauen in Männerkleidern: Sodomie im Hamburg des 18. Jahrhunderts” in Zeitschrift für Sexualforschung 9: 226-27. Monter, E. William. 1985. “Sodomy and Heresy in Early Modern Switzerland” in Licata, Salvatore J. & Robert P. Petersen (eds). The Gay Past: A Collection of Historical Essays. Harrington Park Press, New York. ISBN 0-918393-11-6 (Also published as Journal of Homosexuality, Vol. 6, numbers 1/2, Fall/Winter 1980.) Murray, Jacqueline. 1996. "Twice marginal and twice invisible: Lesbians in the Middle Ages" in Handbook of Medieval Sexuality, ed. Vern L. Bullough and James A. Brundage, Garland Publishing, pp. 191-222 Puff, Helmut. 1997. “Localizing Sodomy: The ‘Priest and sodomite' in Pre-Reformation Germany and Switzerland” in Journal of the History of Sexuality 8:2 165-195 Puff, Helmut. 2000. "Female Sodomy: The Trial of Katherina Hetzeldorfer (1477)" in Journal of Medieval and Early Modern Studies: 30:1, 41-61. Robinson, David Michael. 2001. “The Abominable Madame de Murat'” in Merrick, Jeffrey & Michael Sibalis, eds. Homosexuality in French History and Culture. Harrington Park Press, New York. ISBN 1-56023-263-3 Roelens, Jonas. 2015. “Visible Women: Female Sodomy in the Late Medieval and Early Modern Southern Netherlands (1400-1550)” in BMGN - Low Countries Historical Review vol. 130 no. 3. Sears, Clare. 2015. Arresting Dress: Cross-Dressing, Law, and Fascination in Nineteenth-Century San Francisco. Durham: Duke University Press. ISBN 978-0-8223-5758-2 Traub, Valerie. 2002. The Renaissance of Lesbianism in Early Modern England. Cambridge University Press, Cambridge. ISBN 0-521-44885-9 Van der Meer, Theo. 1991. “Tribades on Trial: Female Same-Sex Offenders in Late Eighteenth-Century Amsterdam” in Journal of the History of Sexuality 1:3 424-445. Velasco, Sherry. 2000. The Lieutenant Nun: Transgenderism, Lesbian Desire and Catalina de Erauso. University of Texas Press. ISBN 0-292-78746-4 Velasco, Sherry. 2011. Lesbians in Early Modern Spain. Vanderbilt University Press, Nashville. ISBN 978-0-8265-1750-0 Vermeil. 1765. Mémoire pour Anne Grandjean. Louis Cellot, Paris. Vicinus, Martha. 2004. Intimate Friends: Women Who Loved Women, 1778-1928. University of Chicago Press, Chicago. ISBN 0-226-85564-3 A transcript of this podcast is available here. Links to the Lesbian Historic Motif Project Online Website: http://alpennia.com/lhmp Blog: http://alpennia.com/blog RSS: http://alpennia.com/blog/feed/ Twitter: @LesbianMotif Discord: Contact Heather for an invitation to the Alpennia/LHMP Discord server The Lesbian Historic Motif Project Patreon Links to Heather Online Website: http://alpennia.com Email: Heather Rose Jones Mastodon: @heatherrosejones@Wandering.Shop Bluesky: @heatherrosejones Facebook: Heather Rose Jones (author page)

Eagles legend and Pro Football Hall of Famer Brian Dawkins joins Cliff on behalf of Boehringer & Lilly's It Takes 2 health initiative and discussed his outstanding career. B-Dawk also discussed the similarities between the 2024 Eagles and his 2004 Eagles, who reached the Super Bowl. Plus, he ranks the top three hits he's ever made. Email: Ringerphilly@gmail.com The Ringer is committed to responsible gaming. Please check out rg-help.com to find out more, or listen to the end of the episode for additional details. Host: Cliff Augustin Producer: Cliff Augustin Music Composed By: Teddy Grossman and Jackson Greenberg Learn more about your ad choices. Visit podcastchoices.com/adchoices

Germany, Europe's most powerful economy, will hold elections in February after the collapse of Chancellor Scholz's ruling coalition. Stephen Sackur speaks to Peter Boehringer, who is a senior MP for the far-right Alternative for Deutschland party. Is his party too extreme to be a serious contender for national power?

Odenwälder wegen Beteiligung an geplanter Entführung Karl Lauterbachs verurteilt, Streit vor Gericht nach Corona-Impfungen und geplante Strafzölle für Importe aus Europa könnten Boehringer Ingelheim und Merck in Darmstadt nach US-Wahl hart treffen. Das und mehr hören Sie heute im Podcast. Alle Hintergründe zu den Nachrichten finden Sie hier: https://www.echo-online.de/politik/politik-deutschland/corona-impfschaeden-wie-erfolgreich-die-klagen-waren-4158563 https://www.echo-online.de/lokales/kreis-darmstadt-dieburg/landkreis-darmstadt-dieburg/axtangriff-in-ober-ramstadt-geschah-die-tat-im-wahn-4163264 https://www.echo-online.de/lokales/rheinland-pfalz/urteil-in-terror-prozess-haftstrafe-fuer-reichsbuerger-4171335 https://www.echo-online.de/lokales/darmstadt/messerangriff-auf-studentin-taeter-macht-verwirrten-eindruck-4172006 https://www.echo-online.de/lokales/darmstadt/darmstadts-kleinparteien-stemmen-sich-gegen-poseck-plaene-4163313 https://www.echo-online.de/wirtschaft/wirtschaft-hessen-und-rheinland-pfalz/so-setzt-donald-trump-boehringer-und-merck-unter-druck-4166238 Ein Angebot der VRM.

Qu'est-ce que le VEDOSS et pourquoi ce programme a-t-il été développé ? Quels avantages apporte un diagnostic très précoce pour la gestion de la sclérodermie systémique ?  Quels examens peuvent aider le rhumatologue à diagnostiquer un cas de VEDOSS ?   Quelles sont les découvertes récentes en recherche sur le VEDOSS ?     Le Pr Marie-Elise Truchetet, rhumatologue au CHU de Bordeaux, nous éclaire sur ce sujet.   Liens d'intérêt : Abbvie, Pfizer, Lilly, UCB, Novartis, Boehringer.   L'équipe : Comité scientifique : Pr Jérémie Sellam, Pr Thao Pham, Dr Catherine Beauvais, Dr Véronique Gaud-Listrat, Dr Céline Vidal, Dr Sophie Hecquet.    Animation : Marguerite de Rodellec   Production : MedShake Studio   Soutien institutionnel : Pfizer

Join us as we welcome Sven Sommerlatte, Chief Human Resources Officer at Boehringer Ingelheim, who shares his insights on career strategy for HR leaders. In this episode, he discusses his book "Successful Career Strategy: An HR Practitioner's Guide to Reach Your Dream Job", and how he applied these strategies to shape the HR function at Boehringer. Sven also highlights the importance of self-awareness, passion, and planning in building a successful HR career. Talent is Everywhere is a podcast for people leaders and HR teams who are passionate about education in the workplace to develop all workers. We explore ideas on how to keep talent and how to develop talent in order to create the virtuous circle that builds strong businesses. We'll interview leaders to hear their experiences of how they invested in people. Hosted by Sylvie Milverton.

✘ Werbung: Mein Buch Katastrophenzyklen ► https://amazon.de/dp/B0C2SG8JGH/ Kunden werben Tesla-Kunden ► http://ts.la/theresia5687 Mein Buch Allgemeinbildung ► https://amazon.de/dp/B09RFZH4W1/ - Ein Zuseher stellt mir Fragen über die politische Entwicklung des Landes. Ich beantworte Sie nach bestem Wissen und Gewissen und lasse mich auch auf die Beurteilung der Alternative für Deutschland #afd ein. Im Teil 2 nenne ich journalistische #Medien (Papier und Digital), die noch kritischen #Journalismus verbreiten. - Mein Video mit Marc Friedrich Katastrophenzyklen ► https://youtu.be/RvQpv7Tz_aU Kanal Prof. Homburg ► https://www.youtube.com/@StHomburg Mein Kupferzock 1 ► https://youtu.be/C9cDKAAtWw0 Mein Kupferzock 2 ► https://youtu.be/lVfydLMmTWo axinocapital Hr. Boehringer ► https://youtu.be/ENx4bX7vEwY Gewaltenteilung ► https://youtu.be/dHLw0B90GhQ 60%-92% rot-grüne Journalisten ► https://youtu.be/WOqHXntrWOk ef-magazin der Freiheit ► https://youtu.be/rg3GclCf29s - 0:59:

In this episode, Isabel is joined by Nedim Pipic, Senior Vice President and Global Therapeutic Area Head for Mental Health, Boehringer Ingelheim, to mark World Mental Health Day on 10 October 2024.  Their conversation dives into the unique challenges faced by those living with serious mental illnesses, the impact of media representation and the role pharma can play in transforming treatment and quality of life for these patients.  Central to their discussion is the importance of amplifying lived experiences, a key focus of Boehringer's new campaign, Schizophrenia in Real Life: Stories of Challenges, Resilience, and Hope.  The campaign aims to build greater understanding and acceptance of the condition by highlighting the strength and resilience of those living with it. 

Send us a textCurious about why only 26% of Kiwi veterinary nurses plan to stay in their profession until retirement? Join Julie South as she catches up with Associate Professor Laura Harvey, the President of the New Zealand Veterinary Nursing Association, who sheds light on this pretty grim statistic. Julie and Laura talk about the unique challenges faced by New Zealand's veterinary workforce, from rural and cultural dynamics to the impacts of poor remuneration. With insights backed by the Boehringer survey, Laura provides a comprehensive look into the factors contributing to the high turnover rate and what can be done to support these essential healthcare professionals.Julie and Laura also tackle the operational dynamics within veterinary clinics, emphasising the importance of distinguishing between the roles of veterinary nurses and receptionists. With real-world examples from VetStaff, we illustrate how small clinics can thrive by clearly defining these roles, leading to significant improvements in efficiency and growth. Packed with practical advice, this episode is a must-listen for anyone curious about the intricacies of veterinary nursing as a profession in New Zealand veterinary clinics. Tune in for an episode that promises valuable insights and actionable advice!Contemplating your next career move? Tania Bruce - VetStaff's passionate kiwi recruiter - would welcome the opportunity to have a 100% confidential chat with you. Tania's a former Ortho Head Vet Nurse so speaks your language!How to get more bang for your recruitment advertising buckThis is what VetStaff is really good at so if you'd like to stretch your recruitment dollar, please get in touch with Julie because this is something VetStaff can help you with. Committed to DIY-ing your own recruitment?If so, then shining online as a good employer is essential to attracting the types of veterinary professionals who're a perfect cultural fit for your clinic. The VetClinicJobs job board is the place to post your next job vacancy - to find out more get in touch with Lizzie at VetClinicJobs Revive Your Drive - daily 2-minute videos for veterinary employers and employees to help revive their drives at work and at home.

Wieder Verkehrsbehinderungen nach Wasseraustritt in Wiesbaden, neue Debatte um Windräder auf dem Taunuskamm und Höcke hetzt nach Kampagne gegen Familienunternehmen. Das und mehr hören Sie heute im Podcast. Alle Hintergründe zu diesen Themen finden Sie hier: https://www.wiesbadener-kurier.de/lokales/wiesbaden/stadt-wiesbaden/wegen-wasserrohrbruch-frankfurter-strasse-in-wiesbaden-voll-gesperrt-3913580 https://www.wiesbadener-kurier.de/lokales/wiesbaden/stadt-wiesbaden/vollgestellte-garagen-werden-in-wiesbaden-zum-streitthema-3892317 https://www.wiesbadener-kurier.de/sport/fussball/fussball-wiesbaden/nach-abbruch-in-wiesbadener-a-liga-spiel-diese-konsequenzen-drohen-3913618 https://www.wiesbadener-kurier.de/lokales/kreis-rheingau-taunus/idstein-kreis-rheingau-taunus/kritik-an-erneuter-windkraft-absage-in-taunusstein-3902790 https://www.wiesbadener-kurier.de/wirtschaft/wirtschaft-hessen-und-rheinland-pfalz/anti-afd-kampagne-hoecke-hetzt-gegen-boehringer-ingelheim-3914043 Ein Angebot der VRM.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Pfizer is terminating its Duchenne gene therapy program, resulting in the layoff of 150 staff members. Boehringer has acquired startup Nerio for up to $1.3 billion to expand its cancer drug pipeline. Emerging biotech IPOs are showing signs of life after a slow period. GSK has cut vaccine forecasts due to slowing sales of its shingles vaccine. Stakeholders in clinical research are exploring the use of real-world evidence for external control arms. Stryker CEO Kevin Lobo plans to be "very active" in mergers and acquisitions after another successful quarter of orthopedic robot installations. Guardant Health has received FDA approval for a blood test for colon cancer, which could increase screening rates. The FDA approved Tecelra, an engineered T cell therapy, as a breakthrough for solid tumors by Adaptimmune Therapeutics. CMS finalized higher hospital payments for 2025, with a 2.9% increase in inpatient payment rates.Humana expects to lose a few hundred thousand Medicare Advantage members next year due to a reduction in its plan footprint for 2025. Optum is laying off more than 500 workers in California, affecting urgent care locations, clinics, and office workers. A data breach at HealthEquity could impact 4.3 million individuals. The FDA has approved Tecelra, an engineered T cell therapy, as a breakthrough for solid tumors. Revenue cycle management firm R1 RCM is set to go private in an $8.9 billion acquisition deal with private equity firms TowerBrook and Clayton, Dubilier and Rice.Despite concerns about data security and privacy challenges, AI is being used in areas such as science and clinical trials to gain insights, predict patient outcomes, and enhance efficiency within the pharma industry. Pharma is learning from AI tools, moving from hype to a daily reality, with insights being gained on what makes trials successful and how AI can improve various processes within pharma companies.Support the Show.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The biotech industry is experiencing significant growth, with drugmakers in the U.S. and Europe raising $6.8 billion in venture capital funding in the first three months of the year. This trendline explores the evolving biotech market and highlights hotspots of startup activity. Stories included focus on an unorthodox investment firm supporting biotech's 'infrastructure', the rise in private biotech funding, and insights from biotech landlord Alexandria on research clusters and the sector's recovery.A study presented at the Alzheimer's Association International Conference showed that Novo Nordisk's GLP-1 drug liraglutide may slow cognitive decline in Alzheimer's patients by 18% compared to placebo over one year of treatment. Additionally, Novo's diabetes drug Ozempic was found to be linked to a lower risk for tobacco use disorder. Pfizer and Merck reported strong second-quarter earnings exceeding Wall Street expectations. Novo Nordisk's Ozempic was also found to potentially help diabetics quit smoking according to new research. Other news includes AstraZeneca's Calquence achieving positive results in a Phase III trial for CLL and Ventyx ending development of a Tyk2 inhibitor after a Phase II flop in Crohn's disease.Pfizer has decided to quit its Duchenne gene therapy program, resulting in the termination of 150 staff members. Incyte has also trimmed its cancer drug pipeline by discontinuing the development of five experimental treatments. The biotech market is seeing an increase in M&A activity, with companies like Boehringer making deals to add to their cancer drug pipeline. Overall, the industry is evolving with a focus on efficiency, effectiveness, and ethical innovation in clinical research.Sanofi's recent record sales quarter for its immunology drug Dupixent has boosted the company's confidence in its long-term strategy, following a previous dip in share value due to growth target adjustments. The company's spinoff of its consumer unit Opella is part of a trend among big pharma companies to focus on biopharma futures. Sanofi's Dupixent, with an expanding list of indications, is showing long-term value for the company and has the potential to become one of the best-selling drugs in the world by the end of the decade.Cleveland Clinic has appointed its first Chief AI Officer, Ben Shahshahani, to lead the health system's AI strategy, focusing on managing safety, ethics, and data security concerns. Healthcare organizations are facing obstacles in increasing patient response rates through phone communication. Healthcare Dive provides insights and news for healthcare leaders, covering various topics such as health IT, policy & regulation, insurance, digital health, payer-provider partnerships, and value-based care.GSK has partnered with Flagship to help find new drugs and vaccines, similar to recent alliances with Pfizer and Novo Nordisk. Boehringer has acquired startup Nerio for up to $1.3 billion to expand its cancer drug pipeline. Autobahn raised $100 million for neuropsych drugs, while a startup led by former J&J executives, Third Arc Bio, raised $165 million for cancer and immune disease drugs. The competitive market for obesity drugs is growing, with analysts expecting significant revenue from drugs like Novo's and Eli Lilly's.Biopharma Dive provides in-depth coverage of industry news and trends, covering topics from clinical trials to drug pricing and research partnerships.Support the Show.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.GSK is relying on its flagship program to help find new drugs and vaccines, following disappointments with Ventyx's tyk2 drug suffering setbacks. New Amsterdam's heart drug hits trial goals but disappoints investors, and Boehringer adds to its cancer drug pipeline with a deal for startup Nerio. The industry is exploring the use of eClinical technology to improve clinical trials, while stakeholders are looking for more efficient ways to innovate with real-world evidence. Overall, the biopharma industry is facing challenges and setbacks, but also opportunities for growth and development in various areas of research and development.Boehringer Ingelheim has acquired Nerio Therapeutics for $1.3 billion in order to strengthen its immuno-oncology pipeline with novel immune checkpoint inhibitors. Additionally, Adaptimmune is preparing for potential approval of their first-in-class engineered T cell therapy. In other news, Wuxi Apptec's U.S. revenue dropped slightly as the Biosecure Act looms, while the FDA has flagged safety risks of compounded versions of Novo Nordisk's semaglutide. AbbVie's Skyrizi has received EU approval for ulcerative colitis, and Merck's Keytruda in combination with Padcev has been granted a positive opinion by CHMP for urothelial carcinoma. Other updates include FDA approvals for new oral Alzheimer's therapy and expanded labels for Grifols' SCIG therapy. The biopharma industry is also experiencing layoffs at companies such as Cue, Anokion, and Glycomimetics. Biogen is facing challenges with its neuro drugs, including a recent EU regulatory rejection for Leqembi due to concerns about brain swelling. The company also had a setback with an essential tremor treatment developed with Sage Therapeutics. Despite these failures, Biogen and Sage will continue to work together as part of a two-drug development deal. The industry is exploring preclinical modeling as a potential solution to improve the success rate of neuro drug development. Overall, Biogen's development pipeline is under pressure, especially following the withdrawal of the Alzheimer's drug Aduhelm earlier in the year. The company is facing obstacles in gaining traction with its treatments in both the US and European markets.Optum is planning to lay off over 500 workers in California, affecting various healthcare facilities and remote workers. CHS posted a $13 million loss in the second quarter, despite increases in surgical and outpatient volumes. Lawmakers are urged to support nursing home staffing regulations to protect the elderly, rather than overturning them. The resumption of the VA Oracle EHR rollout is being questioned at a subcommittee hearing. Healthcare leaders are encouraged to use digital tools to address the shortage of mental health providers and meet the growing need for mental health services. Overall, the healthcare industry is facing challenges related to patient communication, staffing regulations, and financial losses.Support the Show.

This Day in Legal History: Black Sox Scandal Jury SelectionOn July 5, 1921, jury selection commenced for one of the most infamous trials in baseball history: the Chicago "Black Sox" trial. Eight players from the Chicago White Sox, including the legendary "Shoeless Joe" Jackson, stood accused of conspiring to throw the 1919 World Series against the Cincinnati Reds. The scandal shocked the nation, casting a shadow over America's beloved pastime and questioning the integrity of the sport.The players were charged with accepting bribes from gamblers in exchange for intentionally losing the series. The trial attracted immense public and media attention, with fans eagerly following every development. Despite compelling evidence and confessions from some players, the jury ultimately acquitted all eight defendants.However, the acquittal did not mean exoneration in the eyes of baseball's governing bodies. Newly appointed Baseball Commissioner Kenesaw Mountain Landis took decisive action to restore the sport's integrity. On August 3, 1921, Landis issued a lifetime ban on all eight players involved in the scandal, regardless of the trial's outcome.The "Black Sox" trial remains a significant moment in legal and sports history, illustrating the complex interplay between law, ethics, and professional sports. The trial's legacy endures, serving as a cautionary tale about the dangers of corruption and the importance of maintaining trust in public institutions.A federal judge rejected Boehringer Ingelheim's attempt to block the Biden administration's Medicare Drug Price Negotiation Program, which aims to reduce prescription drug costs. Chief Judge Michael P. Shea ruled against all of Boehringer Ingelheim's claims, stating the program is constitutional. The case centered on whether the Inflation Reduction Act's provision forcing drug companies to agree to a maximum fair price for selected drugs violates constitutional rights.Boehringer Ingelheim argued that the program infringed on the First Amendment (compelled speech), Fifth Amendment (due process and takings clauses), Eighth Amendment (excessive fines), the Administrative Procedure Act, and the unconstitutional conditions doctrine. However, Judge Shea determined that participation in Medicare and Medicaid is voluntary, even if economically incentivized, and the federal government can place conditions on participation in its programs. He clarified that Boehringer Ingelheim was not deprived of property interest since it had the option to withdraw before any data submission was required.Regarding the First Amendment claim, Shea found no support in precedent, likening required communications to standard price regulations. On the Eighth Amendment claim, he noted that Boehringer Ingelheim could not demonstrate a likelihood of success as the argument was novel and lacked precedent.The case, Boehringer Ingelheim Pharmaceuticals, Inc. v. United States Department of Health and Human Services, highlights ongoing legal challenges to the Biden administration's health plan, specifically targeting the reduction of high drug prices under the Inflation Reduction Act. The key issue here is the First Amendment argument, which was a central but unsupported claim in this case. Judge Shea's ruling emphasized that required communications for regulatory compliance do not constitute compelled speech under the First Amendment.Judge Tosses Boehringer Bid to Block Biden Drug Price PlanThe Federal Trade Commission (FTC) faced a significant legal challenge when a Texas federal judge halted its rule banning noncompete clauses across the U.S. Judge Ada Brown sided with the U.S. Chamber of Commerce and a Texas tax firm, arguing that the FTC exceeded its authority. This decision, following recent Supreme Court rulings limiting agency powers, underscores the difficulties the FTC may encounter in implementing new regulations.The FTC's noncompete rule, which was to take effect on September 4, would have impacted around 30 million U.S. workers by prohibiting noncompete clauses that restrict job mobility within the same industry. FTC Chair Lina Khan has been advocating for broader antitrust regulation, including labor markets, but faced opposition from major business groups.This rule, adopted in April with a narrow 3-2 vote, was a rare move for the FTC, which has traditionally addressed competition issues through legal actions rather than broad rulemaking. Despite the FTC's assertion that it has the authority to issue such a rule, Brown ruled that the FTC Act of 1914 does not permit the agency to create substantive rules on unfair competition.Legal experts noted that the FTC's limited history with rulemaking poses challenges for the agency, especially in light of recent Supreme Court decisions that reduce judicial deference to regulatory interpretations. This context complicates the FTC's efforts to enforce the noncompete ban, potentially leading to further legal battles.Brown's ruling referenced the recent Supreme Court decision in Loper Bright Enterprises v. Raimondo, which overturned the Chevron deference principle, further complicating regulatory actions by the FTC. While this particular decision was limited to the plaintiffs in the case, it sets a precedent that could hinder future FTC regulations.FTC Noncompete Ban Freeze Signals Tough Legal Road for AgencyUS judge partially blocks FTC ban on worker noncompete agreements | ReutersA liberal group, Accountable.US, filed a complaint with the Washington DC Attorney General alleging that the Conservative Partnership Institute (CPI), a nonprofit organization employing former White House Chief-of-Staff Mark Meadows, improperly funneled money to cover Meadows' legal bills related to investigations into efforts to overturn the 2020 election. The complaint states that CPI gave a $1.2 million grant to Personnel Policy Operations (PPO), another nonprofit, which then transferred $1.1 million to the Constitutional Rights Defense Fund to fund legal defenses for Trump allies, including Meadows.Accountable.US argues that CPI's actions violate its nonprofit status, which requires operations to benefit the public, not partisan operatives. The complaint calls for the dissolution of CPI and PPO, claiming they serve private interests rather than public purposes. The DC Attorney General has the authority to dissolve nonprofits that fail to operate in the public interest.CPI, a key organization in conservative circles preparing for a potential second Trump administration, paid Meadows a substantial salary in 2022. The complaint underscores that nonprofits must not engage in political campaigning or private benefit operations to maintain their tax-exempt status. Additionally, another liberal group, Campaign for Accountability, previously filed a similar complaint with the IRS against CPI.The takeaway here is the requirement for nonprofits to operate for public benefit to retain tax-exempt status. This case raises questions about whether CPI and PPO violated these rules by financially supporting Meadows and other Trump allies.Mark Meadows Nonprofit Funneled Cash for Legal Bills, Group SaysA $170 million legal fee request from lawyers at Grant & Eisenhofer and three other firms remains unresolved after a Brooklyn federal judge rejected their antitrust settlement with Visa and Mastercard. The settlement, following nearly 20 years of litigation, aimed to reduce the interchange fees merchants pay for credit card transactions. Visa and Mastercard would have paid up to $113.3 million and $56.6 million, respectively, to cover the legal fees if the settlement was approved.Judge Margo Brodie ruled that the settlement did not sufficiently address the merchants' concerns, despite agreeing with the fee request terms. She argued that Visa and Mastercard could withstand a more substantial settlement, noting that merchants paid $100 billion in interchange fees in 2023 alone. The proposed agreement would have marginally reduced swipe fees and imposed caps for five years but still required merchants to honor all Visa and Mastercard transactions.The ruling means lawyers must renegotiate better terms with Visa and Mastercard, extending the timeline for any resolution. Despite rejecting the settlement, Brodie's decision cannot be appealed and would be difficult to overturn.Opposition to the settlement came from major retailers and trade groups, who deemed it inadequate. The National Retail Federation, while not yet addressing the legal fee request, expressed broader concerns over the deal.In related legal fee news, Tesla and the legal team that voided Elon Musk's $56 billion stock options will argue over compensation, with the plaintiffs seeking around $7 billion, contrasting Tesla's suggestion of $13.6 million. Additionally, firms involved in a $48 million settlement with Progressive over undervalued wrecked cars seek up to $16 million in fees, and Hagens Berman and Cohen Milstein were awarded $51.6 million in a chicken price-fixing case.Legal Fee Tracker: Lawyers' $170 million payday in limbo in credit card swipe fee case | ReutersThis week's closing theme is by John Philip Sousa.This week's closing theme features the renowned American composer and conductor, John Philip Sousa. Known as "The March King," Sousa is celebrated for his extraordinary contributions to military and patriotic music. Born in Washington, D.C., in 1854, Sousa's career spanned more than five decades, during which he composed over 130 marches, as well as numerous operettas, suites, songs, and waltzes. His music epitomizes the spirit and vibrancy of American patriotism, making him a household name and a significant figure in American music history.Sousa began his musical journey at a young age, joining the U.S. Marine Band as an apprentice when he was only 13. He later became the band's conductor, elevating its status to the finest military band in the country. After leaving the Marine Band, Sousa formed his own civilian band, which gained international fame and toured extensively. His impact on American music extends beyond composition; he also championed music education and the development of the sousaphone, a marching band instrument named in his honor.Today, we highlight one of his most famous marches, "The Liberty Bell." Composed in 1893, this piece is instantly recognizable and has been used in various contexts, including as the theme for the British comedy series "Monty Python's Flying Circus." "The Liberty Bell" was originally intended for an operetta that never came to fruition, but it found new life as a standalone march. The piece is a perfect example of Sousa's ability to blend melodic ingenuity with rousing rhythmic patterns, capturing the essence of American optimism and pride. The title was inspired by a suggestion from Sousa's wife after they saw a picture of the Liberty Bell in a magazine.Without further ado, enjoy "The Liberty Bell" by John Philip Sousa. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

Audio roundup of selected biopharma industry content from Scrip over the business week ended 14 June 2024. In this episode: Boehringer best in MASH?; biopharma funding on an upswing?; Moderna's combo jab; clinical trial recover from pandemic; and Astellas's US commercial head speaks. https://scrip.citeline.com/SC150442/Quick-Listen-Scrips-Five-MustKnow-Things Playlist: https://soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Ralph welcomes back Bishop William J. Barber to discuss the upcoming Poor People's Campaign March and Assembly in Washington, DC on June 29th, as well as Bishop Barber's new book "WHITE POVERTY: How Exposing Myths About Race and Class Can Reconstruct American Democracy." Then Ralph is joined by Phil Mattera from Good Jobs First to discuss their new report on corporate misbehavior, "The High Cost of Misconduct: Corporate Penalties Reach the Trillion-Dollar Mark."Bishop William Barber is President and Senior Lecturer of Repairers of the Breach, which was established to train communities in moral movement building. He is Co-chair of the Poor People's Campaign: A National Call for Moral Revival, and Founding Director and Professor at the Center for Public Theology and Public Policy at Yale Divinity School.  His new book is White Poverty: How Exposing Myths About Race and Class Can Reconstruct American Democracy.I might add, for our listeners, a lot of these social safety measures have been long enacted and are operating in Western Europe, in Canada, even in places like Taiwan and Japan—like full health insurance, and a lot of the labor rights, the absence of voter suppression, higher minimum wages. And in Western Europe, they have abolished poverty—as we know it in the United States. Ralph NaderOne thing that people are saying why they're interested [in the Poor People's Campaign] is because this is not just a gathering of a day, and it's not just a gathering for a few high-profile people to speak. The messengers are going to be the impacted people, and many of the people are committing to the larger effort of mobilizing these poor low wealth voters.Bishop William BarberIt's not just “saving the democracy”, Ralph. It's what kind of democracy do we want to save?Bishop William BarberWe see the kindredness of issues and oppression— that if these bodies can come together and unite, not by ignoring the issue of race, but by dealing with it and dealing with race and class together and recognizing the power that they have together, there can be some real fundamental change.Bishop William BarberPhil Mattera serves as Violation Tracker Project Director and Corporate Research Project Director at Good Jobs First. Mr. Mattera is a licensed private investigator; author of four books on business, labor and economics; and a long-time member of the National Writers Union. His blog on corporate research and corporate misbehavior is the Dirt Diggers Digest, and has written more than 70 critical company profiles for the Corporate Rap Sheets section of the Corporate Research Project website. He is co-author, with Siobhan Standaert, of the new report “The High Cost of Misconduct: Corporate Penalties Reach the Trillion-Dollar Mark”. This is a big problem with the Justice Department—it has this addiction to leniency agreements and it wants to give companies an opportunity not to have to plead guilty when there actually are criminal cases brought against them. So they offer them these strange deals—non-prosecution and deferred-prosecution agreements. And the theory is that the company is going to be so shaken up by the possibility of a criminal charge that they'll clean up their act, and they'll never do bad things again. But what we've seen over and over again is the companies get the leniency agreement and then they break the rules again. And sometimes the Justice Department responds by giving them another leniency agreement. So it turns the whole process into a farce. Phil MatteraWe're always interested in more transparency about both the misconduct and about enforcement actions. We feel that there's no justification for agencies to ever keep this information secret…I think there needs to be more pressure on companies, particularly high profile companies that have been involved in these offenses. A lot of companies seem to think that they pay their penalty, they just move on, and it's as if it's as if it never happened.Phil MatteraIn Case You Haven't Heard with Francesco DeSantisNews 6/5/241.  In Mexico, Claudia Sheinbaum has been elected president in a landslide. Sheinbaum is the hand-picked successor of Mexican president Andrés Manuel López Obrador, or AMLO, who is termed out but leaves office with an 80% approval rating, per Gallup. Sheinbaum is Mexico's first woman president; she is also the country's first Jewish president. In addition to years of service in government, Sheinbaum is an accomplished climate scientist who worked with the Intergovernmental Panel on Climate Change. During her campaign, Sheinbaum published a list of 100 commitments she will pursue as president. Front and center among these are climate-related goals. Sustainability magazine reports “[Sheinbaum] has committed to investing more than…$13 billion in new energy projects by 2030, focusing on wind and solar power generation and modernising hydroelectric facilities.” We urge the U.S. government to follow suit.2. Stacy Gilbert, a senior civil military adviser for the U.S. State Department, resigned last Tuesday, alleging that “The state department falsified a report…to absolve Israel of responsibility for blocking humanitarian aid flows into Gaza,” per the Guardian. Gilbert claims “that report's conclusion went against the overwhelming view of state department experts who were consulted.” As the article notes, this report was a high stakes affair. Had the State Department found that the Israeli government had violated international humanitarian law, and linked those violations to U.S.-supplied weapons, there would have been serious consequences regarding the legality of American military support. In addition to Gilbert, “Alexander Smith, a contractor for the US Agency for International Development… resigned on Monday…[saying] he was given a choice between resignation and dismissal after preparing a presentation on maternal and child mortality among Palestinians.”3. Per the Jeruslam Post, “South African International Relations and Cooperation Minister Naledi Pandor affirmed…that the United States would be next if the International Criminal Court (ICC) is allowed to prosecute Israeli leadership.” Pandor “went on to claim that nations and officials who provide military and financial assistance for Israel's war against Hamas in Gaza ‘will be liable for prosecution…' [and]…noted that a group of 140 international lawyers are currently working on a class action suit against non-Israelis, including South Africans, who have been serving in Israel's military.” International law experts like Bruce Fein have previously warned that the United States' material support for Israel during this genocidal campaign makes this country a co-belligerent in this war and therefore liable for prosecution by the ICC.4. Liberal Israeli news outlet Haaretz has published a shocking report related to the recent revelations concerning Mossad's intimidation campaign against the ICC. According to Haaretz's report, the paper was “about to publish details of the affair” in 2022, when “security officials thwarted it.” Al Jazeera adds that the Haaretz journalist behind the story, Gur Megiddo was told during his meeting with an Israeli security official, that if he published, he “would suffer the consequences and get to know the interrogation rooms of the Israeli security authorities from the inside.” This story highlights how deeply Israel has descended into authoritarianism, seeking to bully and silence not only international watchdogs, but their own domestic journalists.5. Prem Thakker of the Intercept is out with an outrageous story of censorship at elite law reviews. According to Mr. Thakker, “In November, human rights lawyer Rabea Eghbariah was set to be the first Palestinian published in the Harvard Law Review. Then his essay was killed. [On June 3rd], he became the first [Palestinian published] in the Columbia Law Review. Then the Board of Directors took the whole site down.” As I write this, the Columbia Law Review website still says it is “under maintenance.”6. Lauren Kaori Gurley, Labor Reporter at the Washington Post, reports “16 [thousand] academic workers at UC San Diego, UC Santa Barbara, and UC Irvine will [go on] strike…according to their union… They will join 15 [thousand] workers already on strike at UCLA, UC Santa Cruz, and UC Davis over the university's response to pro-Palestine protests on campus.” We commend these academic workers for leveraging their most powerful tool – their labor – on behalf of their fellow students and those suffering in Palestine.7. More Perfect Union reports “The FBI has raided landlord giant Cortland Management over algorithmic price-fixing collusion. Cortland is allegedly part of a bigger conspiracy coordinated by software firm RealPage to raise rents across the country through price-fixing and keeping apartments empty.” Paired with the recent oil price fixing lawsuit and the announcement from retailers that they are lowering prices on many consumer goods, a new picture of inflation is starting to emerge – one that has less to do with macroeconomic reality and more to do with plain old corporate greed.8. Vermont has passed a new law making it the first state in the nation to demand that “fossil fuel companies…pay a share of the damage caused by climate change,” per AP. Per this report, “Under the legislation, the Vermont state treasurer, in consultation with the Agency of Natural Resources, would provide a report…on the total cost to Vermonters and the state from the emission of greenhouse gases from Jan. 1, 1995, to Dec. 31, 2024… [looking] at the effects on public health, natural resources, agriculture, economic development, housing and other areas.” Paul Burns of the Vermont Public Interest Research Group said of the law “For too long, giant fossil fuel companies have knowingly lit the match of climate disruption without being required to do a thing to put out the fire…Finally, maybe for the first time anywhere, Vermont is going to hold the companies most responsible for climate-driven floods, fires and heat waves financially accountable for a fair share of the damages they've caused.”9. Following months of pressure and a probe led by Senator Bernie Sanders, Boehringer – one of the largest producers of inhalers – has announced they will cap out of pocket costs for the lifesaving devices at $35, per Common Dreams. Boehringer used to charge as much as $500 for an inhaler in the U.S., while the same product sold in France for just $7. Sanders, continuing this crusade, said "We look forward to AstraZeneca moving in the same direction…in the next few weeks, and to GlaxoSmithKline following suit in the coming months,” and added “We are waiting on word from Teva, the fourth major inhaler manufacturer, as to how they will proceed."10. Finally, the Justice Department has unsealed an indictment charging Bill Guan, the Chief Financial Officer of the Epoch Times newspaper with “participating in a transnational scheme to launder at least…$67 million of illegally obtained funds.” The Epoch Times is the mouthpiece of a bizarre anti-Communist Chinese cult known as the Falun Gong, famous for their outlandish beliefs such as that proper mastery of qigong can be “used to develop the ability to fly, to move objects by telekinesis and to heal diseases,” per the New York Times. The Falun Gong is also the entity behind the Shen Yun performances and their ubiquitous billboards. In recent years, the Epoch Times has gone all-in on Right-wing propaganda and fake news, with close ties to the Trump White House and campaign, as the Guardian has detailed. We urge the Justice Department to pursue this indictment to the hilt and shut down this rag that has become a cancer within our republic.This has been Francesco DeSantis, with In Case You Haven't Heard. Get full access to Ralph Nader Radio Hour at www.ralphnaderradiohour.com/subscribe

In this Trending News Europe episode, Jack, Jen, and Ollie discuss recent newsworthy items from across Europe, including the impact of and deterrents against “no shows” at medical appointments, the role bacteria play in cancer treatment, and inequalities in the rare disease market, along with the steps being taken to ease these issues.Podcast Tags: healthcare, healthcare news, life sciences, public health, France, medical, bacteria, cancer, immunotherapy, chemotherapy, microbiome, rare disease, Germany, Italy, health disparity  Source Links:Dutch hospitals use AI to solve no-show patient problems that cost them millions  Cancellations of NHS care are having serious impacts on two-thirds of patients  Would charging patients for missed appointments help fund the NHS?  GP 'no shows' cost Norfolk NHS more than 1m in a one month  France planning €5 no-show fees in a bid to improve community healthcare  France divided over ‘no-show tax' for patients failing medical appointments   Researchers compile detailed catalog of bacteria living in cancer metastases  Boehringer builds out cancer capabilities with $500M deal for bacteria-focused Swiss biotech  The key to young onset bowel cancer may be gut bacteria  The mystery of microbes that live inside tumours  Diversity of Bacteria in Cancer Metastases  It's the Little Things: A Role for Bacteria in Cancer Treatment   The UK is missing out on EU collaboration to improve treatment for rare diseases  Overcoming the burden of rare diseases in Europe  Stronger together in the fight against rare diseases  Is Europe on track to be the leader in rare diseases?  Right here, right now European public health policies must start giving people living with rare diseases a fair chance  New rare diseases action plan on horizon, Europe at turning point  Europe needs new 360 rare diseases strategy   Panel – Jack Young, Jen Burke, Ollie May  Research & Production – Karan Pandya  Recording & Editing – Mike Liberto, Rachel Skonecki   For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

Brian Boehringer joins the show

En este episodio descubriremos cómo las empresas están redefiniendo sus estrategias de capacitación y desarrollo para prepararse ante los desafíos de la próxima era. Traemos un caso real de una empresa que está marcando la diferencia con sus acciones: BMW Group. Esta compañía no solo está revolucionando la industria automotriz, sino que también está liderando iniciativas innovadoras para capacitar a sus colaboradores y estudiantes universitarios en habilidades esenciales para la transición hacia la electromovilidad. Nos acompaña Daniel Boehringer Human Resources Director de BMW Group para la planta de San Luis Potosi para contarnos más.

Amazons The Lesbian Historic Motif Podcast - Episode 282 with Heather Rose Jones In this episode we talk about: Possible historic sources for the Amazon myth Classical and post-classical Amazons Homoeroticism and Amazon characters Sources mentionedAmer, S. 2009. “Medieval Arab Lesbians and 'Lesbian-Like'” in Journal of the History of Sexuality, 18(2), 215-236. Blythe, James M. 2001. “Women in the Military: Scholastic Arguments and Medieval Images of Female Warriors” in History of Political Thought, vol. 22 no. 2, pp.242-269. Boehringer, Sandra (trans. Anna Preger). 2021. Female Homosexuality in Ancient Greece and Rome. Routledge, New York. ISBN 978-0-367-74476-2 Crane, Susan. 1996. “Clothing and Gender Definition: Joan of Arc,” in Journal of Medieval and Early Modern Studies 26:2 : 297-320. Dekker, Rudolf M. and van de Pol, Lotte C. 1989. The Tradition of Female Transvestism in Early Modern Europe. Macmillan, London. ISBN 0-333-41253-2 Donoghue, Emma. 2010. Inseparable: Desire Between Women in Literature. Alfred A. Knopf, New York. ISBN 978-0-307-27094-8 Habib, Samar. 2007. Female Homosexuality in the Middle East: Histories and Representations. Routledge, New York. ISBN 78-0-415-80603-9 Hinds, Leonard. 2001. “Female Friendship as the Foundation of Love in Madeleine de Scudéry's ‘Histoire de Sapho'” in Merrick, Jeffrey & Michael Sibalis, eds. Homosexuality in French History and Culture. Harrington Park Press, New York. ISBN 1-56023-263-3 Kruk, Remke. 1998. “The Bold and the Beautiful: Women and ‘fitna' in the S?rat Dh?t al-Himma: The Story of N?r?” in Women in the Medieval Islamic World: Power, Patronage, and Piety, ed. Gavin R. G. Hambly. New York: St. Martin's Press. ISBN 0-312-21057-4 Mayor, Adrienne. 2014. The Amazons: Lives and Legends of Warrior Women across the Ancient World. Princeton: Princeton University Press. ISBN 978-0-691-14720-8 Morrison, Susan Signe. 2017. A Medieval Woman's Companion. Oxbow Books, Oxford. ISBN 978-1-78570-079-8 Murray, Stephen O. 1997. “Woman-Woman Love in Islamic Societies” in Islamic Homosexualities - Culture, History, and Literature, ed. by Stephen O. Murray & Will Roscoe. New York University Press, New York. ISBN 0-8147-7468-7 Schwarz, Kathryn. 2000. Tough Love: Amazon Encounters in the English Renaissance. Durham: Duke University Press. ISBN 0-8223-2599-3 Stephens, Dorothy. 1994. “Into Other Arms: Amoret's Evasion” in Queering the Renaissance ed. by Jonathan Goldberg. Duke University Press, Durham and London. ISBN 0-8223-1381-2 Wahl, Elizabeth Susan. 1999. Invisible Relations: Representations of Female Intimacy in the Age of Enlightenment. Stanford University Press, Stanford. ISBN 0-8047-3650-2 Walen, Denise A. 2005. Constructions of Female Homoeroticism in Early Modern Drama. New York: Palgrave MacMillan. ISBN 978-1-4039-6875-3 Westphal, Sarah. 1997. "Amazons and Guérillères" in Medieval Feminist Newsletter, No. 23: 24-28. Wilde, Lyn Webster. 1999. On the Trail of the Women Warriors. London: Constable. ISBN 0-09-148080-3 This topic is discussed in one or more entries of the Lesbian Historic Motif Project here: Amazons A transcript of this podcast is available here. Links to the Lesbian Historic Motif Project Online Website: http://alpennia.com/lhmp Blog: http://alpennia.com/blog RSS: http://alpennia.com/blog/feed/ Twitter: @LesbianMotif Discord: Contact Heather for an invitation to the Alpennia/LHMP Discord server The Lesbian Historic Motif Project Patreon Links to Heather Online Website: http://alpennia.com Email: Heather Rose Jones Mastodon: @heatherrosejones@Wandering.Shop Bluesky: @heatherrosejones Facebook: Heather Rose Jones (author page)

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. 3M has named William Brown as its new CEO, replacing Michael Roman who has led the company since 2018. Abbott has recalled its HeartMate LVAD communication system due to reported injuries linked to the device malfunctioning. 3M's board has approved a health spinoff, with investors set to receive shares of Solventum. An FDA panel has backed Lumicell's agent for breast cancer imaging tool, despite some risks. A report by AdvaMed has found racial disparities in care, particularly in cardiovascular procedures, and proposes solutions to address these issues. The medtech industry is seeing trends in digital health and AI applications, which are becoming more prominent in the medical device space. Cigna is capping cost increases for pricey GLP-1 weight loss drugs, showing how major players are adapting to meet high demand for these medications.Pfizer's antibody-drug conjugate, ADCetris, showed improved overall survival in patients with relapsed or refractory diffuse large b-cell lymphoma when used with rituximab or lenalidomide. The unique trial design of the study is expected to be the focus of an upcoming advisory committee meeting. Additionally, Roche presented promising mid-stage data for an investigational therapy for Alzheimer's disease, showing rapid and robust amyloid plaque reduction. Acadia Pharmaceuticals is terminating development of its antipsychotic drug after it failed to demonstrate a statistically significant improvement over placebo in a late-stage study. Merck is making a potential $1 billion bet on Pearl Bio's genomically recoded organisms. FDA updates guidelines for Alzheimer's drug development, while biopharma companies like BMS and Innovent Bio announce layoffs and site closures.Roche is focusing on its next Alzheimer's drug after setbacks, while Acadia faces a setback in a schizophrenia trial. Boehringer and Sosei Heptares have teamed up in a deal for a schizophrenia drug. Biotech stock fundings are on track for the best quarter in 3 years. ALS doctors are preparing for tough conversations with patients after a surprise trial failure, and Acadia's drug failure sets back the company's expansion plans. Other news includes the use of social determinants of health data to identify patient populations for weight loss drugs, and a deal between Boehringer and Sosei Heptares to develop medicines for neurological diseases. Publicly traded biotech companies have raised nearly $10 billion in follow-on stock offerings in January and February, driving a sector recovery according to Jefferies.The text discusses the concept of precision medicine and the All of Us research program, which aims to build a diverse health database. The program has revealed risk factors for Alzheimer's disease. The delay in the approval of Eli Lilly's drug for Alzheimer's, Donanemab, is seen as a potential opportunity to improve drug development and pave the way for a more personalized approach to treatment. Additionally, a liquid biopsy for colorectal cancer screening from Guardant Health could make precision medicine in cancer more feasible.In an upcoming webinar, marketers can learn how to execute bigger ideas in a simpler and more cost-effective way using creative automation. Many businesses struggle to balance costs, speed, and creative quality in today's complex marketing landscape. By automating creatives, marketers can accelerate digital ad production, distribution, and impact. Automation enables marketers to increase collaboration between teams, accelerate ad production, and execute bigger ideas more efficiently.Participants can register for the webinar to discover how automation can help streamline marketing efforts and drive ROI.

Schulz, Sandra www.deutschlandfunk.de, Interviews

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: optimistic outlook for biopharma IPOs; Boehringer's promising MASH results; Viking emerges as obesity contender; Incyte looks to portfolio diversification; and a look at China's HPV vaccine market. https://scrip.citeline.com/SC149879/Quick-Listen-Scrips-Five-MustKnow-Things

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/JTS865. CME/MOC/AAPA credit will be available until November 13, 2024.Revolutionizing Solid Tumor Treatment, Unleashing the Potential of Antibody–Drug Conjugates: How to Make the Most of the Latest Clinical Evidence to Enhance Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerPaolo Tarantino, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; and Lilly.Grant/Research Support from AstraZeneca.Speaker for AstraZeneca; Daiichi Sankyo, Inc.; and F. Hoffmann-La Roche Ltd/Genentech, Inc.Faculty/PlannerErika Hamilton, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcus Biosciences, Inc.; Arvinas, Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, lnc.; Ellipses Pharma; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Greenwich LifeSciences, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Lilly; Loxo Oncology; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Orum Therapeutics; Pfizer; Relay Therapeutics; Seagen Inc.; and Verascity Science (all paid to institution).Grant/Research Support from AbbVie Inc.; Accutar Biotechnology Inc; Acerta Pharma; ADC Therapeutics SA; Akeso Biophanna Co., Ltd.; Amgen Inc.; Aravive; Artios Pharma; Arvinas, Inc.; AstraZeneca; AtlasMedx, Inc.; BeiGene, lnc.; Black Diamond Therapeutics, Inc.; Bliss Biopharmaceutical (Hangzhou) Co., Ltd.; Boehringer lngelheim Pharmaceuticals, lnc.; Cascadian Therapeutics; Clovis Oncology; Compugen; Cullinan Oncology, Inc.; Curis, Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dana-Farber Cancer Institute; Dantari; Deciphera Pharmaceuticals, Inc.; Duality Biologics; eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Elucida Oncology, Inc.; EMD Serano, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; H3 Biomedicine Inc.; Harpoon Therapeutics; HUTCHMED (China) Limited; lmmunoGen, Inc.; lmmunomedics, Inc.; lncyte; Infinity Pharmaceuticals, Inc.; lnvestisBio; Jacobio Pharmaceuticals Group Co., Ltd.; K-Group Beta, lnc.; Karyopharm; Lilly; Loxo Oncology; Lycera; MabSpace Biosciences Co., Ltd.; MacroGenics, Inc.; Medlmmune, LLC; Mersana Therapeutics; Merus; Millennium Pharmaceuticals, Inc.; Molecular Templates, Inc.; Novartis Pharmaceuticals Corporation; Nucana; Olema Oncology; OncoMed Pharmaceuticals, Inc.; Onconova Therapeutics; Oncothyreon; ORIC Pharmaceuticals, Inc.; Orinove lnc.; Pfizer; PharmaMar; Pieris Pharmaceuticals, Inc.; Pionyr lmmunotherapeutics; Plexxikon; Radius Health, lnc.; Regeneron Pharmaceuticals Inc.; Relay Therapeutics; Repertoire Immune Medicines; Rgenix Inc.; Seagen lnc.; Sermonix Pharmaceuticals; Shattuck Labs Inc.; Stemcentrx, Inc.; Sutro Biopharma, lnc.; Syndax; Syros Pharmaceuticals, Inc.; Taiho Oncology, Inc.; Taplmmune lnc; TESARO, Inc.; Tolmar Pharmaceuticals, Inc.; Torque Therapeutics, Inc.; Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; zenithepigenetics; and Zymeworks (all paid to institution).Faculty/PlannerYelena Y. Janjigian*, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie, Inc.; AmerisourceBergen; Arcus Biosciences; AskGene Pharma, Inc.; Astellas Pharma Inc.; AstraZeneca; Basilea Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo Inc.; GlaxoSmithKline; Guardant Health; Imugene Limited; Inspirna, Inc.; Lilly; Merck and Co., Inc.; Merck Serono; Mersana Therapeutics Inc.; Pfizer; Rgenix Inc.; Seagen Inc.; Silverback Therapeutics (ARS Pharmaceuticals) and Zymeworks Inc.Grant/Research Support from Arcus Biosciences; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Cycle for Survival; Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Inspirna, Inc.; Lilly; Merck and Co., Inc.; National Cancer Institute; Transcenta Holding; and U.S. Department of Defense.Stock Shareholder in Inspirna, Inc.Faculty/PlannerAntonio Passaro, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Daiichi Sankyo, Inc.; GSK; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Global Services, LLC.; Lilly; Merck Sharp and Dohme; Mundipharma International; Novartis AG; Pfizer; and Takeda Pharmaceutical Company Limited.Grant/Research Support from ArriVent Biopharma; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Global Services, LLC.; Lilly; Merck Serono; Merck Sharp and Dohme; Mirati Therapeutics, Inc.; Pfizer; and RMC Pharmaceutical Solutions Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/JTS865. CME/MOC/AAPA credit will be available until November 13, 2024.Revolutionizing Solid Tumor Treatment, Unleashing the Potential of Antibody–Drug Conjugates: How to Make the Most of the Latest Clinical Evidence to Enhance Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerPaolo Tarantino, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; and Lilly.Grant/Research Support from AstraZeneca.Speaker for AstraZeneca; Daiichi Sankyo, Inc.; and F. Hoffmann-La Roche Ltd/Genentech, Inc.Faculty/PlannerErika Hamilton, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcus Biosciences, Inc.; Arvinas, Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, lnc.; Ellipses Pharma; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Greenwich LifeSciences, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Lilly; Loxo Oncology; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Orum Therapeutics; Pfizer; Relay Therapeutics; Seagen Inc.; and Verascity Science (all paid to institution).Grant/Research Support from AbbVie Inc.; Accutar Biotechnology Inc; Acerta Pharma; ADC Therapeutics SA; Akeso Biophanna Co., Ltd.; Amgen Inc.; Aravive; Artios Pharma; Arvinas, Inc.; AstraZeneca; AtlasMedx, Inc.; BeiGene, lnc.; Black Diamond Therapeutics, Inc.; Bliss Biopharmaceutical (Hangzhou) Co., Ltd.; Boehringer lngelheim Pharmaceuticals, lnc.; Cascadian Therapeutics; Clovis Oncology; Compugen; Cullinan Oncology, Inc.; Curis, Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dana-Farber Cancer Institute; Dantari; Deciphera Pharmaceuticals, Inc.; Duality Biologics; eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Elucida Oncology, Inc.; EMD Serano, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; H3 Biomedicine Inc.; Harpoon Therapeutics; HUTCHMED (China) Limited; lmmunoGen, Inc.; lmmunomedics, Inc.; lncyte; Infinity Pharmaceuticals, Inc.; lnvestisBio; Jacobio Pharmaceuticals Group Co., Ltd.; K-Group Beta, lnc.; Karyopharm; Lilly; Loxo Oncology; Lycera; MabSpace Biosciences Co., Ltd.; MacroGenics, Inc.; Medlmmune, LLC; Mersana Therapeutics; Merus; Millennium Pharmaceuticals, Inc.; Molecular Templates, Inc.; Novartis Pharmaceuticals Corporation; Nucana; Olema Oncology; OncoMed Pharmaceuticals, Inc.; Onconova Therapeutics; Oncothyreon; ORIC Pharmaceuticals, Inc.; Orinove lnc.; Pfizer; PharmaMar; Pieris Pharmaceuticals, Inc.; Pionyr lmmunotherapeutics; Plexxikon; Radius Health, lnc.; Regeneron Pharmaceuticals Inc.; Relay Therapeutics; Repertoire Immune Medicines; Rgenix Inc.; Seagen lnc.; Sermonix Pharmaceuticals; Shattuck Labs Inc.; Stemcentrx, Inc.; Sutro Biopharma, lnc.; Syndax; Syros Pharmaceuticals, Inc.; Taiho Oncology, Inc.; Taplmmune lnc; TESARO, Inc.; Tolmar Pharmaceuticals, Inc.; Torque Therapeutics, Inc.; Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; zenithepigenetics; and Zymeworks (all paid to institution).Faculty/PlannerYelena Y. Janjigian*, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie, Inc.; AmerisourceBergen; Arcus Biosciences; AskGene Pharma, Inc.; Astellas Pharma Inc.; AstraZeneca; Basilea Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo Inc.; GlaxoSmithKline; Guardant Health; Imugene Limited; Inspirna, Inc.; Lilly; Merck and Co., Inc.; Merck Serono; Mersana Therapeutics Inc.; Pfizer; Rgenix Inc.; Seagen Inc.; Silverback Therapeutics (ARS Pharmaceuticals) and Zymeworks Inc.Grant/Research Support from Arcus Biosciences; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Cycle for Survival; Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Inspirna, Inc.; Lilly; Merck and Co., Inc.; National Cancer Institute; Transcenta Holding; and U.S. Department of Defense.Stock Shareholder in Inspirna, Inc.Faculty/PlannerAntonio Passaro, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Daiichi Sankyo, Inc.; GSK; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Global Services, LLC.; Lilly; Merck Sharp and Dohme; Mundipharma International; Novartis AG; Pfizer; and Takeda Pharmaceutical Company Limited.Grant/Research Support from ArriVent Biopharma; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Global Services, LLC.; Lilly; Merck Serono; Merck Sharp and Dohme; Mirati Therapeutics, Inc.; Pfizer; and RMC Pharmaceutical Solutions Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/JTS865. CME/MOC/AAPA credit will be available until November 13, 2024.Revolutionizing Solid Tumor Treatment, Unleashing the Potential of Antibody–Drug Conjugates: How to Make the Most of the Latest Clinical Evidence to Enhance Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerPaolo Tarantino, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; and Lilly.Grant/Research Support from AstraZeneca.Speaker for AstraZeneca; Daiichi Sankyo, Inc.; and F. Hoffmann-La Roche Ltd/Genentech, Inc.Faculty/PlannerErika Hamilton, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcus Biosciences, Inc.; Arvinas, Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, lnc.; Ellipses Pharma; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Greenwich LifeSciences, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Lilly; Loxo Oncology; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Orum Therapeutics; Pfizer; Relay Therapeutics; Seagen Inc.; and Verascity Science (all paid to institution).Grant/Research Support from AbbVie Inc.; Accutar Biotechnology Inc; Acerta Pharma; ADC Therapeutics SA; Akeso Biophanna Co., Ltd.; Amgen Inc.; Aravive; Artios Pharma; Arvinas, Inc.; AstraZeneca; AtlasMedx, Inc.; BeiGene, lnc.; Black Diamond Therapeutics, Inc.; Bliss Biopharmaceutical (Hangzhou) Co., Ltd.; Boehringer lngelheim Pharmaceuticals, lnc.; Cascadian Therapeutics; Clovis Oncology; Compugen; Cullinan Oncology, Inc.; Curis, Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dana-Farber Cancer Institute; Dantari; Deciphera Pharmaceuticals, Inc.; Duality Biologics; eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Elucida Oncology, Inc.; EMD Serano, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; H3 Biomedicine Inc.; Harpoon Therapeutics; HUTCHMED (China) Limited; lmmunoGen, Inc.; lmmunomedics, Inc.; lncyte; Infinity Pharmaceuticals, Inc.; lnvestisBio; Jacobio Pharmaceuticals Group Co., Ltd.; K-Group Beta, lnc.; Karyopharm; Lilly; Loxo Oncology; Lycera; MabSpace Biosciences Co., Ltd.; MacroGenics, Inc.; Medlmmune, LLC; Mersana Therapeutics; Merus; Millennium Pharmaceuticals, Inc.; Molecular Templates, Inc.; Novartis Pharmaceuticals Corporation; Nucana; Olema Oncology; OncoMed Pharmaceuticals, Inc.; Onconova Therapeutics; Oncothyreon; ORIC Pharmaceuticals, Inc.; Orinove lnc.; Pfizer; PharmaMar; Pieris Pharmaceuticals, Inc.; Pionyr lmmunotherapeutics; Plexxikon; Radius Health, lnc.; Regeneron Pharmaceuticals Inc.; Relay Therapeutics; Repertoire Immune Medicines; Rgenix Inc.; Seagen lnc.; Sermonix Pharmaceuticals; Shattuck Labs Inc.; Stemcentrx, Inc.; Sutro Biopharma, lnc.; Syndax; Syros Pharmaceuticals, Inc.; Taiho Oncology, Inc.; Taplmmune lnc; TESARO, Inc.; Tolmar Pharmaceuticals, Inc.; Torque Therapeutics, Inc.; Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; zenithepigenetics; and Zymeworks (all paid to institution).Faculty/PlannerYelena Y. Janjigian*, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie, Inc.; AmerisourceBergen; Arcus Biosciences; AskGene Pharma, Inc.; Astellas Pharma Inc.; AstraZeneca; Basilea Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo Inc.; GlaxoSmithKline; Guardant Health; Imugene Limited; Inspirna, Inc.; Lilly; Merck and Co., Inc.; Merck Serono; Mersana Therapeutics Inc.; Pfizer; Rgenix Inc.; Seagen Inc.; Silverback Therapeutics (ARS Pharmaceuticals) and Zymeworks Inc.Grant/Research Support from Arcus Biosciences; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Cycle for Survival; Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Inspirna, Inc.; Lilly; Merck and Co., Inc.; National Cancer Institute; Transcenta Holding; and U.S. Department of Defense.Stock Shareholder in Inspirna, Inc.Faculty/PlannerAntonio Passaro, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Daiichi Sankyo, Inc.; GSK; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Global Services, LLC.; Lilly; Merck Sharp and Dohme; Mundipharma International; Novartis AG; Pfizer; and Takeda Pharmaceutical Company Limited.Grant/Research Support from ArriVent Biopharma; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Global Services, LLC.; Lilly; Merck Serono; Merck Sharp and Dohme; Mirati Therapeutics, Inc.; Pfizer; and RMC Pharmaceutical Solutions Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/JTS865. CME/MOC/AAPA credit will be available until November 13, 2024.Revolutionizing Solid Tumor Treatment, Unleashing the Potential of Antibody–Drug Conjugates: How to Make the Most of the Latest Clinical Evidence to Enhance Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerPaolo Tarantino, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; and Lilly.Grant/Research Support from AstraZeneca.Speaker for AstraZeneca; Daiichi Sankyo, Inc.; and F. Hoffmann-La Roche Ltd/Genentech, Inc.Faculty/PlannerErika Hamilton, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcus Biosciences, Inc.; Arvinas, Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, lnc.; Ellipses Pharma; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Greenwich LifeSciences, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Lilly; Loxo Oncology; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Orum Therapeutics; Pfizer; Relay Therapeutics; Seagen Inc.; and Verascity Science (all paid to institution).Grant/Research Support from AbbVie Inc.; Accutar Biotechnology Inc; Acerta Pharma; ADC Therapeutics SA; Akeso Biophanna Co., Ltd.; Amgen Inc.; Aravive; Artios Pharma; Arvinas, Inc.; AstraZeneca; AtlasMedx, Inc.; BeiGene, lnc.; Black Diamond Therapeutics, Inc.; Bliss Biopharmaceutical (Hangzhou) Co., Ltd.; Boehringer lngelheim Pharmaceuticals, lnc.; Cascadian Therapeutics; Clovis Oncology; Compugen; Cullinan Oncology, Inc.; Curis, Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dana-Farber Cancer Institute; Dantari; Deciphera Pharmaceuticals, Inc.; Duality Biologics; eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Elucida Oncology, Inc.; EMD Serano, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; H3 Biomedicine Inc.; Harpoon Therapeutics; HUTCHMED (China) Limited; lmmunoGen, Inc.; lmmunomedics, Inc.; lncyte; Infinity Pharmaceuticals, Inc.; lnvestisBio; Jacobio Pharmaceuticals Group Co., Ltd.; K-Group Beta, lnc.; Karyopharm; Lilly; Loxo Oncology; Lycera; MabSpace Biosciences Co., Ltd.; MacroGenics, Inc.; Medlmmune, LLC; Mersana Therapeutics; Merus; Millennium Pharmaceuticals, Inc.; Molecular Templates, Inc.; Novartis Pharmaceuticals Corporation; Nucana; Olema Oncology; OncoMed Pharmaceuticals, Inc.; Onconova Therapeutics; Oncothyreon; ORIC Pharmaceuticals, Inc.; Orinove lnc.; Pfizer; PharmaMar; Pieris Pharmaceuticals, Inc.; Pionyr lmmunotherapeutics; Plexxikon; Radius Health, lnc.; Regeneron Pharmaceuticals Inc.; Relay Therapeutics; Repertoire Immune Medicines; Rgenix Inc.; Seagen lnc.; Sermonix Pharmaceuticals; Shattuck Labs Inc.; Stemcentrx, Inc.; Sutro Biopharma, lnc.; Syndax; Syros Pharmaceuticals, Inc.; Taiho Oncology, Inc.; Taplmmune lnc; TESARO, Inc.; Tolmar Pharmaceuticals, Inc.; Torque Therapeutics, Inc.; Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; zenithepigenetics; and Zymeworks (all paid to institution).Faculty/PlannerYelena Y. Janjigian*, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie, Inc.; AmerisourceBergen; Arcus Biosciences; AskGene Pharma, Inc.; Astellas Pharma Inc.; AstraZeneca; Basilea Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo Inc.; GlaxoSmithKline; Guardant Health; Imugene Limited; Inspirna, Inc.; Lilly; Merck and Co., Inc.; Merck Serono; Mersana Therapeutics Inc.; Pfizer; Rgenix Inc.; Seagen Inc.; Silverback Therapeutics (ARS Pharmaceuticals) and Zymeworks Inc.Grant/Research Support from Arcus Biosciences; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Cycle for Survival; Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Inspirna, Inc.; Lilly; Merck and Co., Inc.; National Cancer Institute; Transcenta Holding; and U.S. Department of Defense.Stock Shareholder in Inspirna, Inc.Faculty/PlannerAntonio Passaro, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Daiichi Sankyo, Inc.; GSK; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Global Services, LLC.; Lilly; Merck Sharp and Dohme; Mundipharma International; Novartis AG; Pfizer; and Takeda Pharmaceutical Company Limited.Grant/Research Support from ArriVent Biopharma; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Global Services, LLC.; Lilly; Merck Serono; Merck Sharp and Dohme; Mirati Therapeutics, Inc.; Pfizer; and RMC Pharmaceutical Solutions Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Former big leaguer Brian Boehringer joins the show

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. ## Insulet CFO, Wayde McMillan, has left the company to join 3M's health spinoff. Baxter has hired a new CFO, Joel Grade, who previously worked in the food industry at Sysco for 25 years. Akura Medical has secured $35 million in funding to pursue FDA clearance for its thrombectomy device. Duke researchers have found that an app improves autism screening in a study funded by the NIH. Invitae's test for hereditary cancers has gained FDA de novo approval. The FDA has expanded its total product life cycle program to cover neurological devices and could enroll up to 45 additional devices over the next year.In other news, Lilly has announced changes to its executive team, with Mike Mason retiring and being replaced by Patrik Jonsson. Novartis has completed the spinoff of its generic drug unit, Sandoz. Sanofi will pay $500 million to collaborate with Teva on the development of an anti-gut disease therapy called TL1A. Moderna has claimed positive results in an early study for its combination COVID-19 and flu vaccine. A new report shows that only two out of eight biotech companies that priced offerings since July 1 are currently trading at or above their debut share price.Moving on to healthcare industry news, Kaiser Permanente workers have initiated the largest strike in history. Progressive lawmakers Elizabeth Warren and Pramila Jayapal have called for closer examination of the $3.3 billion deal between UnitedHealth and Amedisys. A report from Fitch Ratings suggests that nonprofit hospitals will continue to face labor-related challenges. Molina has lost the anticipated Indiana Medicaid contract.French pharmaceutical company Sanofi has signed a potential $1.5 billion deal with Teva Pharmaceuticals. The FDA has raised concerns about Amgen's confirmatory trial for its lung cancer drug Lumakras. Ten companies have registered to participate in Medicare's drug price negotiation program. Regeneron and Intellia are expanding their collaboration on CRISPR/Cas9 gene editing. Eli Lilly is deepening its oncology pipeline with the acquisition of Point Biopharma. Boehringer is offering an unbranded biosimilar at an 81% discount to AbbVie's Humira. Several biopharmaceutical companies have recently implemented layoffs. The FDA has rejected Lilly's eczema treatment.Investors are funding longevity companies that focus on developing therapeutics to interfere with the aging process. Some companies have managed to secure funding despite a decline in investment in the sector. Ten companies have registered to participate in the Medicare drug price negotiation program. Eli Lilly is shuffling its executive team as it awaits FDA approval for its weight loss drug. The

Alternative for Germany | Interview with Peter Boehringer by lotuseaters.com

Stephen Sackur speaks to Peter Boehringer, Vice Chairman of Germany's far-right Alternative for Deutschland party. They are anti-immigrant, anti-EU, anti-military aid for Ukraine, and are running second in national polls. Does their rise threaten Germany's stability?

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.MilliporeSigma has introduced its optimized VirusExpress platform for the development and manufacturing of lentiviral vectors. The platform aims to provide industry-leading titers, robust recovery, streamlined workflows, and reduced development timelines. MilliporeSigma will be showcasing its VirusExpress platform at various events.MilliporeSigma is the U.S. and Canada life science business of Merck KGaA.The FDA panel has rejected Medtronic's renal denervation device, stating that the risks outweigh the benefits. Levita has received 510(k) clearance for its surgeon-controlled arm for magnetic procedures. Draeger's ventilator sound insulation has triggered an FDA class I recall due to concentrations of a potentially carcinogenic foam component being above acceptable levels. Recor has gained FDA panel backing for its high blood pressure device, although there are concerns over the long-term durability of the treatment.Cigna has announced that it will remove prior authorizations for 25% of its services, aiming to reduce administrative burdens and streamline healthcare process for patients.CVS has launched a new venture called Cordavis, which will work directly with manufacturers to market or co-produce low-cost biologic drugs. CMS has threatened to cut hospices from Medicare if they cannot prove their legitimacy.Pharmaceutical companies are preparing for the next wave of COVID-19 infections caused by new variants of the virus. Researchers are concerned about infectious strains like "eris," which have been detected in large cities in the United States. Public health leaders and the pharmaceutical industry are working to develop and distribute vaccines to combat the new variants.Royalty Pharma has made its first gene therapy deal by buying into Ferring's cancer treatment adstiladrin for up to $500 million. Startup Cellares has raised $255 million in funding, with investors pouring cash into cell therapy production. Agenus is set to lay off 25% of its staff and trim its pipeline in a push for cancer drugs. Roche's surprise study results have spurred new optimism for TIGIT drugs.Pharmaceutical companies Pfizer, Moderna, and Novavax are preparing for the next wave of COVID-19 infections caused by new variants of the virus. Public health leaders and the pharmaceutical industry are working to develop and distribute vaccines to combat the new variants.Apellis has discovered faulty needles in its probe of a rare side effect of its eye drug, Syfovre. Boehringer has filed a lawsuit to block Medicare's new power to negotiate certain drug prices, claiming it is unconstitutional. Regeneron has rebounded after winning FDA approval for its longer-lasting vision loss drug, high-dose Eylea. Dexcom and Abbott are ramping up direct-to-consumer marketing in their fight for a larger share of the growing diabetes market. The FDA has approved Pfizer's RSV vaccine, called Abrysvo, for use in pregnancy. Blue Shield of California has dropped CVS Caremark as its pharmacy benefit manager.The FDA panel has given its support to Recor's renal denervation device for the treatment of high blood pressure.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. Medtronic has raised its earnings forecast due to improvements in its supply chain and diabetes business. The company also provided an update on its planned divestment of its monitoring and respiratory interventions segments. Meanwhile, orthopedic device maker Zimmer Biomet announced a CEO transition, with COO Ivan Tornos taking over as the new CEO. Axonics has appointed Kari Keese as CFO following the retirement of co-founder Dan Dearen. In an opinion piece, David Persing from Cepheid discussed the importance of diagnostic testing in addressing antibiotic shortages. Dexcom and Abbott are ramping up direct-to-consumer marketing efforts as they compete for a share of the growing diabetes market.Epic and Microsoft have announced an expansion of their partnership to accelerate the use of generative AI in healthcare. Veradigm, a health IT company, has received its third notice of noncompliance from Nasdaq. Cano Health has appointed a permanent CEO after its founder stepped down from the board. A new report from cybersecurity firm Critical Insights highlights the increasing scale of cyber attacks on healthcare providers. CVS Health has announced layoffs in several states.Pfizer has received FDA approval for its RSV vaccine, called Abrysvo, making it the first maternal immunization approved to protect newborns from the respiratory virus. Boehringer has filed a lawsuit to block Medicare's new power to negotiate certain drug prices. Foundery aims to accelerate early immune drug research by providing scientific and investment support to researchers. Congressman Adam Smith shared his personal struggles with mental health and how it has shaped his perspective on healthcare and pharmaceutical policy. Fulcrum is rejoining the sickle cell drug race as the FDA lifts a study hold.Dr. Vivian Cheung is challenging workplace discrimination against scientists with disabilities in a lawsuit. The article highlights the importance of recognizing and supporting scientists with disabilities. The text promotes a playbook that outlines an omnichannel strategy for achieving true patient centricity and improved patient outcomes in the pharmaceutical industry. The playbook helps companies integrate disparate data sets and navigate change through a coordinated three-step process.Foundery aims to accelerate early immune drug research by providing research grants and drug development support to researchers. Gilead Sciences has partnered with targeted drug startup Tentarix in its latest research bet. Genesis has raised $200 million in a Series B funding round for AI drug discovery research. Merck's acquired drug has shown positive results in a large kidney cancer study. Bruker plans to acquire Phenomex and its cell research tools for $108 million as the life science tools sector is ripe for consolidation.That's all for today. Stay tuned for more updates in the Pharma and Biotech world. Goodbye!

     DER AMERIKANISCHE SÜDWESTEN UND LAKE POWELL VOM HAUSBOOT AUS! Hey Leute, heute habe ich für Euch Peter Böhringer im Podcast zu Gast. In Brasilien geboren und aufgewachsen, in der Schweiz studiert und nun in den USA beheimatet, fotografiert Peter die Four Corners Region in den Vereinigen Staaten. Tief in den Wüstenabschnitten des Südwesten […]

Former big leaguer Brian Boehringer is a great friend of the show! Brian joins us to talk a little bit of Cardinals.

Brian Boehringer is a great friend of the show, and he joins The Press Box once again to talk Cardinals baseball! Listen in to hear Brian's hot takes!

Brian Boehringer rejoins his buddy Frank to talk some baseball with an emphasis on the birds.

A school nurse was busted for sleeping with a student at Vianney which raises a ton of questions. Brian Boehringer is a long-time friend of the show, and he makes another appearance to talk some baseball with Frank!

Frank transitions into a little Cardinal conversation with longtime friend of the show and former pro player Brian Boehringer.

Marlene Engelhorn will ihr großes Millionenerbe zu 90 Prozent gleich weiterreichen. Schließlich könne sie nichts dafür, dass ihre Familie mit den Namen BASF und Boehringer verbunden ist. Große Erbschaften seien im Wortsinne unverdient, schadeten der Demokratie und müssten von Staats wegen abgeschöpft werden. Moderation: Norbert Joa

This week on Pharm5: NM vs. Purdue Pharma, et al. Antibiotic timing in bloodstream infections Spevigo for pustular psoriasis flares Annual COVID-19 boosters Dolutegravir for pregnant patients living with HIV1 Connect with us! Listen to our podcast: Pharm5 Watch us on TikTok: @LizHearnPharmD Follow us on Twitter: @LizHearnPharmD References Siegel D. Three major pharmacy operators begin latest opioid trial in New Mexico, watch online via CVN. CVN News. https://bit.ly/3RtFcQ9. Published September 7, 2022. Accessed September 8, 2022. Pierson B. Pharmacy Operators Walmart, Walgreens, Kroger begin opioid trial in New Mexico. Reuters. https://reut.rs/3Rwi43e. Published September 6, 2022. Accessed September 8, 2022. Van Heuverswyn J, Valik JK, van der Werff SD, Hedberg P, Giske C, Nauclér P. Association between time to appropriate antimicrobial treatment and 30-day mortality in patients with bloodstream infections: A retrospective cohort study. Clinical Infectious Diseases. September 2022. doi:10.1093/cid/ciac727 Boehringer. https://bit.ly/3x7N1mi. Published September 1, 2022. Accessed September 8, 2022. Spevigo. Package Insert. Boehringer Ingelheim Pharmaceuticals, Inc; 2022. Bendix A. Covid vaccines will likely become annual like flu shots, health officials say. NBCNews.com. https://nbcnews.to/3cWpcXU. Published September 6, 2022. Accessed September 8, 2022. Statement by President Biden on FDA and CDC authorizing updated COVID-19 vaccines. The White House. https://bit.ly/3KYpABy. Published September 6, 2022. Accessed September 8, 2022. Patel K, Huo Y, Jao J, et al. Dolutegravir in pregnancy as compared with current HIV regimens in the United States. New England Journal of Medicine. 2022;387(9):799-809. doi:10.1056/nejmoa2200600